瑞普生物
(300119)
| 流通市值：64.31亿 | | | 总市值：89.44亿 |
| 流通股本：3.35亿 | | | 总股本：4.66亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 821,616,475.9 | 3,069,933,116.78 | 1,746,806,365.21 | 1,099,038,124.02 |
| 营业收入 | 821,616,475.9 | 3,069,933,116.78 | 1,746,806,365.21 | 1,099,038,124.02 |
| 二、营业总成本 | 694,874,920.33 | 2,690,140,421.73 | 1,466,821,630.31 | 930,264,855.6 |
| 营业成本 | 482,898,269.73 | 1,799,722,621.6 | 884,008,727.7 | 565,794,235.7 |
| 税金及附加 | 5,832,045.84 | 26,346,455.03 | 16,770,627.63 | 11,587,393.19 |
| 销售费用 | 100,376,582.8 | 451,383,069.54 | 287,789,963.33 | 180,183,413.34 |
| 管理费用 | 49,054,825.1 | 188,944,340.45 | 124,969,273.64 | 78,868,510.09 |
| 研发费用 | 47,940,755.91 | 196,537,745.61 | 135,162,744.28 | 83,481,968.78 |
| 财务费用 | 8,772,440.95 | 27,206,189.5 | 18,120,293.73 | 10,349,334.5 |
| 其中:利息费用 | 9,181,009.35 | 31,214,673.37 | 21,717,594.87 | 13,330,968.7 |
| 其中:利息收入 | 625,210.59 | 4,969,935.23 | 3,798,131.31 | 2,907,517.78 |
| 加:公允价值变动收益 | 25,328,670.23 | -10,707,752.8 | 23,485,986.01 | 14,891,764.47 |
| 加:投资收益 | -701,082.24 | 9,142,829.12 | 1,580,137.03 | 1,643,608.1 |
| 资产处置收益 | 1,061.15 | -16,698.12 | 8,426.89 | -764.95 |
| 资产减值损失(新) | 373,473.73 | -19,849,519.54 | 382,169.91 | 382,169.91 |
| 信用减值损失(新) | -19,476,374.62 | -19,456,021.42 | -18,427,216.54 | -9,274,281.38 |
| 其他收益 | 5,073,106.48 | 34,262,426.62 | 17,064,992.56 | 12,664,166.29 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 137,340,410.3 | 373,167,958.91 | 304,079,230.76 | 189,079,930.86 |
| 加:营业外收入 | 221,917.66 | 1,598,005.56 | 1,305,761.7 | 1,033,640.47 |
| 减:营业外支出 | 2,130,159.16 | 6,476,839.56 | 3,096,113.45 | 1,803,400.96 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 135,432,168.8 | 368,289,124.91 | 302,288,879.01 | 188,310,170.37 |
| 减:所得税费用 | 15,327,402.5 | 38,455,221.73 | 38,106,138.18 | 20,501,658.93 |
| 六、净利润 | 120,104,766.3 | 329,833,903.18 | 264,182,740.83 | 167,808,511.44 |
| 持续经营净利润 | 120,104,766.3 | 329,833,903.18 | 264,182,740.83 | 167,808,511.44 |
| 归属于母公司股东的净利润 | 115,984,657.96 | 300,722,269.32 | 244,736,518.03 | 159,139,372.47 |
| 少数股东损益 | 4,120,108.34 | 29,111,633.86 | 19,446,222.8 | 8,669,138.97 |
| (一)基本每股收益 | 0.25 | 0.65 | 0.53 | 0.35 |
| (二)稀释每股收益 | 0.25 | 0.65 | 0.53 | 0.35 |
| 九、综合收益总额 | 120,104,766.3 | 329,833,903.18 | 264,182,740.83 | 167,808,511.44 |
| 归属于母公司股东的综合收益总额 | 115,984,657.96 | 300,722,269.32 | 244,736,518.03 | 159,139,372.47 |
| 归属于少数股东的综合收益总额 | 4,120,108.34 | 29,111,633.86 | 19,446,222.8 | 8,669,138.97 |
| 公告日期 | 2025-04-26 | 2025-04-03 | 2024-10-30 | 2024-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |